Cargando…

Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients

BACKGROUND: HIV-monoinfected patients may be at risk for significant liver fibrosis, but its prevalence and determinants in these patients are unknown. Since HIV-monoinfected patients do not routinely undergo liver biopsy, we evaluated the prevalence and risk factors of significant hepatic fibrosis...

Descripción completa

Detalles Bibliográficos
Autores principales: DallaPiazza, Michelle, Amorosa, Valerianna K, Localio, Russell, Kostman, Jay R, Lo Re, Vincent
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876168/
https://www.ncbi.nlm.nih.gov/pubmed/20465840
http://dx.doi.org/10.1186/1471-2334-10-116
_version_ 1782181676448743424
author DallaPiazza, Michelle
Amorosa, Valerianna K
Localio, Russell
Kostman, Jay R
Lo Re, Vincent
author_facet DallaPiazza, Michelle
Amorosa, Valerianna K
Localio, Russell
Kostman, Jay R
Lo Re, Vincent
author_sort DallaPiazza, Michelle
collection PubMed
description BACKGROUND: HIV-monoinfected patients may be at risk for significant liver fibrosis, but its prevalence and determinants in these patients are unknown. Since HIV-monoinfected patients do not routinely undergo liver biopsy, we evaluated the prevalence and risk factors of significant hepatic fibrosis in this group using the aspartate aminotransferase (AST)-to-platelet ratio index (APRI). METHODS: We conducted a cross-sectional study among HIV-infected patients negative for hepatitis B surface antigen and hepatitis C antibody in the Penn Center for AIDS Research Adult/Adolescent Database. Clinical and laboratory data were collected from the database at enrollment. Hypothesized determinants of significant fibrosis were modifiable risk factors associated with liver disease progression, hepatic fibrosis, or hepatotoxicity, including immune dysfunction (i.e., CD4 T lymphocyte count <200 cells/mm(3), HIV viremia), diseases associated with hepatic steatosis (e.g., obesity, diabetes mellitus), and use of antiretroviral therapy. The primary outcome was an APRI score >1.5, which suggests significant hepatic fibrosis. Multivariable logistic regression identified independent risk factors for significant fibrosis by APRI. RESULTS: Among 432 HIV-monoinfected patients enrolled in the CFAR Database between November 1999 and May 2008, significant fibrosis by APRI was identified in 36 (8.3%; 95% CI, 5.9 - 11.4%) patients. After controlling for all other hypothesized risk factors as well as active alcohol use and site, detectable HIV viremia (adjusted OR, 2.56; 95% CI, 1.02 - 8.87) and diabetes mellitus (adjusted OR, 3.15; 95% CI, 1.12 - 10.10) remained associated with significant fibrosis by APRI. CONCLUSIONS: Significant fibrosis by APRI score was found in 8% of HIV-monoinfected patients. Detectable HIV viremia and diabetes mellitus were associated with significant fibrosis. Future studies should explore mechanisms for fibrosis in HIV-monoinfected patients.
format Text
id pubmed-2876168
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28761682010-05-26 Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients DallaPiazza, Michelle Amorosa, Valerianna K Localio, Russell Kostman, Jay R Lo Re, Vincent BMC Infect Dis Research Article BACKGROUND: HIV-monoinfected patients may be at risk for significant liver fibrosis, but its prevalence and determinants in these patients are unknown. Since HIV-monoinfected patients do not routinely undergo liver biopsy, we evaluated the prevalence and risk factors of significant hepatic fibrosis in this group using the aspartate aminotransferase (AST)-to-platelet ratio index (APRI). METHODS: We conducted a cross-sectional study among HIV-infected patients negative for hepatitis B surface antigen and hepatitis C antibody in the Penn Center for AIDS Research Adult/Adolescent Database. Clinical and laboratory data were collected from the database at enrollment. Hypothesized determinants of significant fibrosis were modifiable risk factors associated with liver disease progression, hepatic fibrosis, or hepatotoxicity, including immune dysfunction (i.e., CD4 T lymphocyte count <200 cells/mm(3), HIV viremia), diseases associated with hepatic steatosis (e.g., obesity, diabetes mellitus), and use of antiretroviral therapy. The primary outcome was an APRI score >1.5, which suggests significant hepatic fibrosis. Multivariable logistic regression identified independent risk factors for significant fibrosis by APRI. RESULTS: Among 432 HIV-monoinfected patients enrolled in the CFAR Database between November 1999 and May 2008, significant fibrosis by APRI was identified in 36 (8.3%; 95% CI, 5.9 - 11.4%) patients. After controlling for all other hypothesized risk factors as well as active alcohol use and site, detectable HIV viremia (adjusted OR, 2.56; 95% CI, 1.02 - 8.87) and diabetes mellitus (adjusted OR, 3.15; 95% CI, 1.12 - 10.10) remained associated with significant fibrosis by APRI. CONCLUSIONS: Significant fibrosis by APRI score was found in 8% of HIV-monoinfected patients. Detectable HIV viremia and diabetes mellitus were associated with significant fibrosis. Future studies should explore mechanisms for fibrosis in HIV-monoinfected patients. BioMed Central 2010-05-13 /pmc/articles/PMC2876168/ /pubmed/20465840 http://dx.doi.org/10.1186/1471-2334-10-116 Text en Copyright ©2010 DallaPiazza et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
DallaPiazza, Michelle
Amorosa, Valerianna K
Localio, Russell
Kostman, Jay R
Lo Re, Vincent
Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients
title Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients
title_full Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients
title_fullStr Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients
title_full_unstemmed Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients
title_short Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients
title_sort prevalence and risk factors for significant liver fibrosis among hiv-monoinfected patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876168/
https://www.ncbi.nlm.nih.gov/pubmed/20465840
http://dx.doi.org/10.1186/1471-2334-10-116
work_keys_str_mv AT dallapiazzamichelle prevalenceandriskfactorsforsignificantliverfibrosisamonghivmonoinfectedpatients
AT amorosavaleriannak prevalenceandriskfactorsforsignificantliverfibrosisamonghivmonoinfectedpatients
AT localiorussell prevalenceandriskfactorsforsignificantliverfibrosisamonghivmonoinfectedpatients
AT kostmanjayr prevalenceandriskfactorsforsignificantliverfibrosisamonghivmonoinfectedpatients
AT lorevincent prevalenceandriskfactorsforsignificantliverfibrosisamonghivmonoinfectedpatients